文献速递炎症性肠病

姜黄素-清黛联合方案治疗活动性溃疡性结肠炎患者:一项随机、双盲、安慰剂对照试验

Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-06-09

该研究评估姜黄素-清黛(CurQD)联合方案对活动性溃疡性结肠炎(UC)的疗效。第二部分为在以色列和希腊开展的安慰剂对照试验,将活动性UC患者按2:1随机分配至肠溶CurQD 3克/天组或安慰剂组治疗8周。结果显示CurQD在诱导临床应答和缓解方面有效,且独特上调黏膜CYP1A1表达。

要点

  • CurQD组第8周共同主要结局达标率43%,安慰剂组8%(P=0.033)。
  • 临床应答率CurQD组85.7% vs 安慰剂组30.7%(P<0.001)。
  • 临床缓解率CurQD组14/28(50%)vs 安慰剂组1/13(8%;P=0.01)。

核心结论

  • 在这项安慰剂对照试验中,CurQD对活动性UC患者的应答和缓解诱导有效。
  • 芳烃受体通路作为潜在UC治疗靶点可能值得进一步研究。

研究设计与样本

  • 第一部分为开放标签试验,评估CurQD在活动性UC患者中的疗效,活动性UC定义为简单临床结肠炎活动指数评分≥5且Mayo内镜子评分≥2。
  • 第二部分为在以色列和希腊开展的安慰剂对照试验,将活动性UC患者按2:1比例随机分配至肠溶CurQD 3克/天组或安慰剂组,治疗8周。
  • 应答患者继续接受姜黄素或安慰剂单药维持治疗额外8周。
  • 通过黏膜细胞色素P450 1A1(CYP1A1)表达评估芳烃受体活化。

主要发现

  • 第一部分中,10例患者中7例应答,10例中3例达到临床缓解。
  • 第二部分42例患者中,第8周共同主要结局在CurQD组和安慰剂组的达标率分别为43%和8%(P=0.033)。
  • 临床应答率CurQD组85.7% vs 安慰剂组30.7%(P<0.001)。
  • 临床缓解率CurQD组14/28(50%)vs 安慰剂组1/13(8%;P=0.01)。
  • 粪钙卫蛋白降低50%的比例CurQD组46.4% vs 安慰剂组15.4%(P=0.08),内镜改善率CurQD组75% vs 安慰剂组20%(P=0.036)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We evaluated the efficacy of herbal combination of curcumin-QingDai (CurQD) in active ulcerative colitis (UC). METHODS: Part I was an open-label trial of CurQD in patients with active UC, defined by a Simple Clinical Colitis Activity Index score of 5 or higher and a Mayo endoscopic subscore of 2 or higher. Part II was a placebo-controlled trial conducted in Israel and Greece, randomizing active UC patients at a 2:1 ratio to enteric-coated CurQD 3 g/d or placebo for 8 weeks. The co-primary outcome was clinical response (reduction in the Simple Clinical Colitis Activity Index of ≥3 points) and an objective response (Mayo endoscopic subscore improvement of ≥1 or a 50% fecal calprotectin reduction). Responding patients continued either maintenance curcumin or placebo alone for an additional 8 weeks. Aryl-hydrocarbon receptor activation was assessed by cytochrome P450 1A1 (CYP1A1) mucosal expression. RESULTS: In part I, 7 of 10 patients responded and 3 of 10 achieved clinical remission. Of 42 patients in part II, the week 8 co-primary outcome was achieved in 43% and 8% of CurQD and placebo patients, respectively (P = .033). Clinical response was observed in 85.7% vs 30.7% (P < .001), clinical remission in 14 of 28 (50%) vs 1 of 13 (8%; P = .01), a 50% calprotectin reduction in 46.4% vs 15.4% (P = .08), and endoscopic improvement in 75% vs 20% (P = .036) in the CurQD and placebo groups, respectively. Adverse events were comparable between groups. By week 16, curcumin-maintained clinical response, clinical remission, and clinical biomarker response rates were 93%, 80%, and 40%, respectively. CurQD uniquely up-regulated mucosal CYP1A1 expression, which was not observed among patients receiving placebo, mesalamine, or biologics. CONCLUSIONS: In this placebo-controlled trial, CurQD was effective for inducing response and remission in active UC patients. The aryl-hydrocarbon receptor pathway may merit further study as a potential UC treatment target. CLINICALTRIALS: gov ID: NCT03720002.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ben-Horin S, Salomon N, Karampekos G, et al. Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2023. PMID: 37302449. doi:10.1016/j.cgh.2023.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。